Journal article

Impact of access to novel therapies on the initial management of castrate-resistant prostate cancer: an Australian multicentre study

Edmond M Kwan, Marie C Semira, Alice RT Bergin, Christine Muttiah, Sophie Beck, Angelyn Anton, David Campbell, Shirley Wong, Mark Rosenthal, Peter Gibbs, Ben Tran



BACKGROUND: The impact of regulatory approvals of new therapies for castration-resistant prostate cancer (CRPC) in Australia is unclear. AIMS: To determine if changes in novel therapy access in Australia affected how clinicians initially managed men with newly diagnosed CRPC. METHODS: Data from patients diagnosed with CRPC from 2013 to 2016 across three Australian hospitals were retrospectively collected. Baseline clinicopathological factors and initial management decision at the time of CRPC development (early treatment (ET) vs deferred treatment (DT)) were recorded. Categorical variables between cohorts were compared by Chi-squared analysis. Cox regression analysis was performed to assess ..

View full abstract